E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Systolic heart failure associated with iron deficiency |
|
E.1.1.1 | Medical condition in easily understood language |
Reduces heart's pumping associated with iron deficiency |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10074631 |
E.1.2 | Term | Systolic heart failure |
E.1.2 | System Organ Class | 100000004849 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the FAIR-HF2 trial is to show that treatment of patients with systolic heart failure and iron deficiency with i.v. iron (Ferric Carboxymaltose, FCM) versus placebo (i.v. NaCl) can reduce the rate of the combined endpoint of recurrent heart failure hospitalisations and cardiovascular death. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives include the demonstration that in these patients treatment with FCM versus placebo can reduce the rate of recurrent cardiovascular hospitalisations, the rate of recurrent hospitalisations of any kind, and of all-cause mortality. An additional aim is to show the cost-effectiveness of the intervention. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients with chronic HFrEF (CHF) of at least 3 months duration and a history of documented LVEF<45% 2. Confirmed presence of ID (ferritin < 100 ng/mL or ferritin 100 - 299 ng/mL with TSAT < 20 %) 3. Serum haemoglobin of 9.5 to 14.0 g/dL 4. At time of screening considered re-stabilized and planned for discharge within next 24 h (NYHA 2 or 3), or stable ambulatory with a HF hospitalisation in the past 12 months (NYHA 2-4), or stable ambulatory with BNP > 100 pg/mL or NT-proBNP > 300 pg/mL or MR-proANP > 120 pmol/L (NYHA 2-4) 5. Written informed consent
|
|
E.4 | Principal exclusion criteria |
1. Hypersensitivity to the active substance, to FCM or any of its excipients 2. Known serious hypersensitivity to other parenteral iron products 3. Anaemia not attributed to iron deficiency, e.g. other microcytic anaemia 4. Evidence of iron overload or disturbances in the utilisation of iron 5. History of severe asthma with known FEV1 <50% 6. Acute or chronic infection 7. Presence of a deficiency for vitamin B12 and/or serum folate (if present, this needs to be corrected first) 8. Use of renal replacement therapy 9. Treatment with an erythropoietin stimulating agent (ESA), any i.v. iron and/or a blood transfusion in the previous 6 weeks prior to randomization. 10. More than 475 500 meters in the initial 6-minutes walking-test Note: We aim to recruit at least half of the patients with an initial 6-minute walking-test below 375 meters
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Combined rate of recurrent hospitalisations for heart failure and of CV death during follow-up |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Combined rate of recurrent CV hospitalisations and of CV death during follow-up • Combined rate of recurrent hospitalisations for any reason and of CV death • Rate of recurrent HF hospitalisations • Rate of recurrent CV hospitalisations • CV mortality • All-cause mortality • Rate of recurrent hospitalisations of any kind • All-cause mortality • CV mortality • Changes in 6-minute walk-test, NYHA functional class, 6-minute walk-test, EQ-5D, and PGA of wellbeing during follow-up (from baseline to vari-ous time-points of follow-up) • Exploratory: Changes in renal, cardiovascular, inflammatory and metabolic parameters from baseline to end of follow-up
Further analyses: For the primary clinical efficacy endpoint, as well as other im-portant clinical endpoints – especially recurrent heart failure hospitalisations, recurrent CV hospitalisations; CV death, all-cause-death, and combinations thereof - a joint meta-analysis with all other relevant controlled clinical trials testing ferric car-boxymaltose and/ or other iv iron formulations versus placebo (e.g. FAIR-HF 1, AFFIRM-HF, CONFIRMHF) will be performed.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At least after 12 month of follow up |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 13 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 61 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 7 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |